Verification evidence is still being completed.
PDF / print export
StemSight Oy
Tampere, Finland
- Verified lead
- Laura Koivusalo
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer and Co-Founder
- 2026 technical specialization
- iPSC-Derived Corneal Cell Therapy, Limbal Stem Cell Deficiency, and Preclinical Ocular ATMP
- Review cycle
- 24 April 2026
- Full address
- Finn-Medi 5, 6th floor, Biokatu 12, 33520 Tampere, Finland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Voima Ventures founder spotlight naming Laura Koivusalo as CEO and Co-founder of StemSight.
- Editorial note
- Tampere preclinical ATMP biotech with named co-founder CEO, EU Horizon-funded SightLeaders project, and an iPSC-derived corneal cell-therapy pipeline.
iPSC-Derived Corneal Cell Therapy, Limbal Stem Cell Deficiency, and Preclinical Ocular ATMP
Public founder CEO disclosure, EU Horizon project documentation, Voima Ventures portfolio recognition
Tampere preclinical ATMP biotech with named co-founder CEO, EU Horizon-funded SightLeaders project, and an iPSC-derived corneal cell-therapy pipeline.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Tampere, Finland
StemSight Oy
iPSC-Derived Corneal Cell Therapy, Limbal Stem Cell Deficiency, and Preclinical Ocular ATMP · Preclinical cell-therapy development
Tampere preclinical ATMP biotech with named co-founder CEO, EU Horizon-funded SightLeaders project, and an iPSC-derived corneal cell-therapy pipeline.
- Lead
- Laura Koivusalo (verified ↗)
- Address
- Finn-Medi 5, 6th floor, Biokatu 12, 33520 Tampere, Finland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Preclinical cell-therapy development
- Capabilities
- iPSC Differentiation · Cell-Therapy Process Development · Preclinical Ocular Therapeutics
- Founded
- 2021
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Laura Koivusalo
Chief Executive Officer and Co-Founder
Full addressFinn-Medi 5, 6th floor, Biokatu 12, 33520 Tampere, Finland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Preclinical cell-therapy development
Tampere, Finland. iPSC-Derived Corneal Cell Therapy, Limbal Stem Cell Deficiency, and Preclinical Ocular ATMP. Review completed on 24 Apr 2026.
Fimea and EMA for future clinical ATMP development
Public founder CEO disclosure, EU Horizon project documentation, Voima Ventures portfolio recognition
iPSC-Derived Corneal Cell Therapy, Limbal Stem Cell Deficiency, and Preclinical Ocular ATMP
Tampere preclinical ATMP biotech with named co-founder CEO, EU Horizon-funded SightLeaders project, and an iPSC-derived corneal cell-therapy pipeline.
Editorial note
StemSight is a Tampere ATMP biotech with named co-founder CEO, a Horizon-funded SightLeaders project, and a corneal cell-therapy pipeline based on iPSC differentiation.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
iPSC Differentiation
Cell-Therapy Process Development
Preclinical Ocular Therapeutics
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
iPSC differentiation workflow
Corneal cell-therapy process development
Preclinical ocular models
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is StemSight Oy located?
- StemSight Oy operates from Finn-Medi 5, 6th floor, Biokatu 12, 33520 Tampere, Finland, Tampere, Finland.
- Who runs StemSight Oy?
- StemSight Oy is led by Laura Koivusalo, Chief Executive Officer and Co-Founder. Verified 24 Apr 2026.
- What does StemSight Oy do?
- Tampere preclinical ATMP biotech with named co-founder CEO, EU Horizon-funded SightLeaders project, and an iPSC-derived corneal cell-therapy pipeline. Core capabilities: iPSC Differentiation, Cell-Therapy Process Development, Preclinical Ocular Therapeutics.
Editorial context
Related technical briefs
Briefs that name Tampere as a covered market or city.